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Abstract
Background: Colorectal cancer (CRC) is a leading cause of cancer-related mortality. CRC incidence and mortality can be
reduced by several screening strategies, including colonoscopy, but randomized CRC prevention trials face significant
obstacles such as the need for large study populations with long follow-up. Therefore, CRC screening strategies will likely
be designed and optimized based on computer simulations. Several computational microsimulation tools have been
reported for estimating efficiency and cost-effectiveness of CRC prevention. However, none of these tools is publicly
available. There is a need for an open source framework to answer practical questions including testing of new screening
interventions and adapting findings to local conditions.
Methods: We developed and implemented a new microsimulation model, Colon Modeling Open Source Tool (CMOST),
for modeling the natural history of CRC, simulating the effects of CRC screening interventions, and calculating the
resulting costs. CMOST facilitates automated parameter calibration against epidemiological adenoma prevalence and CRC
incidence data.
Results: Predictions of CMOST were highly similar compared to a large endoscopic CRC prevention study as well as
predictions of existing microsimulation models. We applied CMOST to calculate the optimal timing of a screening
colonoscopy. CRC incidence and mortality are reduced most efficiently by a colonoscopy between the ages of 56 and 59;
while discounted life years gained (LYG) is maximal at 49–50 years. With a dwell time of 13 years, the most cost-effective
screening is at 59 years, at $17,211 discounted USD per LYG. While cost-efficiency varied according to dwell time it did
not influence the optimal time point of screening interventions within the tested range.
Conclusions: Predictions of CMOST are highly similar compared to a randomized CRC prevention trial as well as those
of other microsimulation tools. This open source tool will enable health-economics analyses in for various countries,
health-care scenarios and CRC prevention strategies. CMOST is freely available under the GNU General Public License at
https://gitlab.com/misselwb/CMOST
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Background
Colorectal cancer (CRC) is the second most common
deadly cancer in the United States [1] and many other
Western countries. It represents an important public health
burden in industrialized countries and increasingly also in
developing countries [2]. Since treatment options for ad-
vanced cancer are limited, current public health strategies
focus on CRC screening for prevention of mortality.
CRC is remarkable for the long-term presence of ad-
enomatous carcinoma precursors [3, 4]. Early adenomas
are, by definition, adenomas with a tubular histology and
a size of less than 10 mm. Advanced adenomas are ei-
ther larger than 10 mm in size or display an advanced
villous or serrated histology. Adenomas are more fre-
quent in males and their frequency increases with age.
While adenomas are infrequently observed before the
age of 30 years, within the screening population of 50–
80 year olds, prevalence rates of at least one early aden-
oma and at least one advanced adenoma are 30% and
6%, respectively [5]. The presence of adenomas is an im-
portant risk factor for subsequent CRC [6].
The natural history of CRC, i.e., the sequence of events
leading to CRC in each individual patient, has not been
sufficiently clarified. For instance, the adenoma dwell
time, i.e., the average time from initiation of an adenoma
until initiation of CRC, remains unknown [7, 8]. Further-
more, several lines of evidence indicate that right sided
CRC (close to cecum) and left sided CRC (close to rec-
tum) differ regarding their biological behavior: a signifi-
cant fraction of right-sided CRC derives from serrated
adenomas with possible faster progression rates and
lower detectability during endoscopy [9, 10].
Endoscopy is an attractive method for CRC screening be-
cause adenomas can be removed by polypectomy during
this intervention, thus effectively preventing CRC [6]. Add-
itional benefits of CRC screening include identification of
high-risk individuals for surveillance via the presence of ad-
enomas. Furthermore, screening detects CRC at earlier
stages with better survival as compared to symptomatic
cancer [11]. The effectiveness of rectosigmoidoscopy, which
only visualizes the left-sided colon, in reducing CRC inci-
dence and mortality was demonstrated in several large ran-
domized controlled studies [12–16]. Colonoscopy, which
visualizes the whole colon, may be similarly effective as rec-
tosigmoidoscopy [17–20], but rigorous randomized con-
trolled trials have been initiated only recently [21]. As such,
the true magnitude of CRC risk reduction by colonoscopy
is still unknown. Despite these limitations, colonoscopy
screening programs have been implemented in several in-
dustrialized countries. It is generally recommended that in-
dividuals between ages 50–75 years undergo screening
every 10 years, an interval which has not been determined
in any systematic way [22]. Alternative CRC screening
methods that have also been shown to reduce CRC
mortality include detection of fecal occult blood in the stool
as a cancer biomarker [23].
The optimal application of CRC screening remains a
central task in gastroenterology. However, most of the
open questions, such as optimal timing of multiple
screening colonoscopies, will likely never be answered
by high-quality clinical studies. Randomized trials of
CRC screening would need a long follow-up of at least
10 years, its costs are unlikely to be covered by commer-
cial sponsors, and patient compliance might be low due
to the (largely unwarranted) perception of colonoscopy
being unpleasant or dangerous. Due to these limitations,
alternative strategies for studying CRC prevention using
computer simulations have been developed.
In microsimulations, a large, simulated, population of
many individual patients is followed throughout individual
lifetimes for colonic lesions. Microsimulations account for
the individual risk for colorectal cancer, the age-dependent
gradual appearance of adenomas, the development of aden-
omas into cancer, and the detection and treatment of CRC.
Assumptions about occurrence and growth rates of aden-
omas are calibrated to reflect the natural history of CRC.
Further, the effect of screening interventions and polypect-
omy can be incorporated into the model. Simulation exper-
iments are appealing, because a calibrated and validated
model allows for the assessment of a wide range of medical
screening interventions, such as multiple screening colon-
oscopies, in a time-efficient and cost-effective manner.
Three microsimulation models, namely Microsimula-
tion Screening Analysis (MISCAN), Colorectal Cancer
Simulated Population model for Incidence and Natural
history (CRC-SPIN), and Simulation Model of Colorectal
Cancer (SimCRC) have been described (http://cisnet.-
cancer.gov/colorectal/ [24]). These models have been
very useful to evaluate various screening interventions
for CRC with a high degree of confidence [25–29], and
they share several features. All models assume that car-
cinomas develop exclusively from adenomas. Adenomas
progress to advanced adenomas or cancer following spe-
cific rules and parameters are fit to match the epidemio-
logically observed prevalence of adenomas, advanced
adenomas, and cancer. However, individual model pre-
dictions differ and depend on model assumptions and
on the choice of parameters [8].
Adenoma dwell time, defined as the time from the ap-
pearance of clinically detectable adenoma to the appear-
ance of carcinoma, presents the window of opportunity
for effective screening. However, the value of this critical
parameter remains unknown. It cannot be determined
empirically since adenomas cannot be left in situ. The
published microsimulation models assume different
values: MISCAN assumes a short adenoma dwell time of
6 years, resulting in rapid adenoma progression and ag-
gressive behavior. By contrast, SimCRC and CRC-SPIN
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use a dwell time of 23 and 18 years, respectively, leading
to slow adenoma progression and more benign behavior
[30]. Differences of MISCAN, SimCRC, and CRC-SPIN
are not restricted to adenoma dwell time, and it remains
unknown which model features are responsible for differ-
ences in predictions. Further, even though general features
of all microsimulation models are described, the models
are not publicly available and hence predictions of these
models cannot be independently reproduced or advanced.
There is a growing awareness towards CRC screening
and its costs and a constant need to determine the cost-
effectiveness of various screening strategies. Further-
more, many new countries with different CRC epidemi-
ology and health-care costs will be implementing CRC
screening programs. Thus, there is an immediate re-
quirement for an open source tool that is transparent,
easily accessible, and adaptable for addressing highly
relevant clinical and health economy questions.
Here, we present Colon Modeling Open Source
Tool (CMOST), a new, open-source CRC microsi-
mulation model. We calibrated our model against
clinical data including a large rectosigmoidoscopy
screening trial and compared it to existing microsi-
mulation tools. We developed three parameteriza-
tions of our model differing in adenoma dwell time.
Our results show that adenoma dwell time influences
some but not all predictions of our CRC microsimu-
lation model. The model offers the flexibility to de-
sign new screening protocols and costs as well as to
reparameterize for the natural history by working
with the automated calibration.
Methods
Characteristics of the CMOST microsimulation model
We developed a new microsimulation model for CRC,
focusing on the natural history as observed by endos-
copy on a macroscopic and histological level. The model
has been implemented in Matlab as the program Colon
Modeling Open Simulation Tool (CMOST). In our
model, colorectal cancer may develop either through ad-
enomatous precursors detected by colonoscopy or in a
non-adenomatous pathway. Once an adenoma has been
transformed into cancer, it can be detected in an asymp-
tomatic state during diagnostic examinations such as en-
doscopy or when it becomes symptomatic (Fig. 1). The
pseudocode illustrating how our CMOST microsimula-
tion program works is given in Table 1.
In our model, an adenoma develops within one of 13
colon segments (Fig. 2). This location remains constant
for the lifetime of a lesion affecting both rate of progres-
sion as well as accessibility and detection by endoscopic
methods such as rectosigmoidoscopy and colonoscopy.
Altogether 6 distinct adenoma stages are distinguished:
Stages I-IV correspond to early adenomas with sizes of
3 mm, 5 mm, 7 mm, and 9 mm, respectively. Stage V
corresponds to an adenoma ≥1 cm or an adenoma with
advanced villous histology, and stage VI corresponds to
an adenoma of size >2 cm.
Fig. 1 Structure of the microsimulation model used in CMOST. Most cancers in CMOST start as adenomas (stages I to VI) and progress to cancer.
Adenomas may be diagnosed and removed by screening interventions. Few cancers appear directly without adenoma precursors. Preclinical
cancer can be diagnosed at an early stage by screening. Cancer develops in four stages. It can be detected by screening or due to symptoms.
After detection, treatment can cure cancer with a stage-dependent probability
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CMOST tracks the history of a general population
from birth until death or a maximum age of 100 years.
Adenoma initiation, progression to advanced adenoma
and cancer, cancer progression, screening, and surveil-
lance are all modeled in time increments of 3 months.
Choice of parameters
The relevant parameters used for the description of the
natural history of CRC are summarized in Table 2, and
their values are provided in the supplementary
Table 1 Pseudocode for the CMOST program flow
implemented in MATLAB
MAIN MODULE OF CMOST: individually tracks every individual in a
population
Input:
- Model parameters determining natural history of CRC
- Settings for CRC screening and surveillance
Output:
- Death year, cause of death and years lost to CRC for each individual
- CRC incidence, prevalence, stages, mode of detection and outcome
for each CRC and each individual
- Adenoma prevalence and adenoma stages for the whole population
- Usage of screening and surveillance interventions
- All CRC related costs
for Year = 1 to 100 and if Alive = ‘YES’
for IndividualNumber = 1 to NumberOfIndividuals
call function AdenomaNaturalHistory(Record)
%— updates the natural history of adenomas and development to
cancer
if (Screening.Mode=’ON’ and Screening.Preference=’COLONOSCOPY’
and Screening.Year=Year) or
(Cancer.Symptomatic=’YES’) or (FollowUp.Year = Year)
%— if colonoscopy is a preferred screening option, or if cancer is
symptomatic or for followup
call function Colonoscopy
if Treatment=’ON’ and (Year-Cancer.DetectionYear) > 5 years
Treatment=’OFF’
elseif Treatment=’ON’ and (Year-Cancer.DetectionYear) < 5 years
call function AddCost(Treatment=’ON’)
if rand > DeathFromCancer.Chance
Alive.Cancer=’NO’
DeathFromCancer.Year = Year % — used for treatment costs in the
last year before death from cancer
elseif rand > DeathFromNaturalCauses.Chance
Alive=’NO’
end IndividualNumber
end Year
function AdenomaNaturalHistory(Record)
% — new adenoma(s) appear (influenced by age, gender, colon
location, individual risk)
Record.(AdenomaStage=I) = Record.(AdenomaStage=I) +
ChanceOfNewAdenoma
% — adenoma progression (influenced by age, gender, colon
location, individual risk)
Record.(AdenomaStage=II to VI) = Record.(AdenomaStage=II to VI) +
AdenomaStageProgression
Record.CancerStage(1) = Record.CancerStage(I) +
AdenomatousCancer(FromAdenomaStage=VI)
+ FastCancer(FromAdenomaStage=I to V) +
DirectCancer(FromNoAdenoma)
Table 1 Pseudocode for the CMOST program flow
implemented in MATLAB (Continued)
Record.CancerStage(2 to 4) = Record.CancerStage(2 to 4) +
CancerStageProgression
Cancer.Symptomatic = ChanceOfSymptoms(Record.CancerStage)
end function AdenomaNaturalHistory
function Colonoscopy(Record)
Adenoma.Detected =
ChanceOfAdenomaDetection(Record.AdenomaStage,
Record.AdenomaLocation)
Cancer.Detected = ChanceOfCancerDetection(Record.CancerStage,
Record.CancerLocation)
if Cancer.Detected = ’YES’
Cancer.DetectionYear = Year
Record.Cancer = 0%— assume curative treatment has been
performed
Treatment = ’ON’
elseif Adenoma.Detected = ’Yes’
Polypectomy = ’YES’
Record.Adenoma = 0%— remove the adenomas by polypectomy
Adenoma.Detected = 0
FollowUp.Year = RecommendedYear % — recommend followup
according to guidelines
if rand > ChanceOfComplication
Complications = ’YES’
If rand > ChanceOfDeathFromComplications
Alive = ’NO’
call function AddCosts(Colonoscopy, Polypectomy, Complications)
end function Colonoscopy
function AddCosts
Cost = Cost + if(Colonoscopy = ’YES’) x InputCost.Colonoscopy +
and in the last year of death from cancerif(Polypectomy = ’YES’) x
InputCost.Polypectomy +
and in the last year of death from cancerif(Complications = ’YES’) x
InputCost.Complications +
and in the last year of death from cancerif(Treatment = ’ON’) x
InputCost.TreatmentCost(Year – Cancer.DetectionYear)
and in the last year of death from cancer%— the treatment cost is
divided into 3 stages: initial, continuing and last year costs for the first
quarter, upto 5 years and in the last year of death from cancer
end function AddCosts
Prakash et al. BMC Medical Informatics and Decision Making  (2017) 17:80 Page 4 of 16
information. Some of these parameters depend on age
and hence are defined by a function, for instance the
age-dependent adenoma initiation risk of an individual
is assumed to be a sigmoidal function. The sigmoid
function was chosen since the benchmark parameter (i.e.
age-dependent adenoma prevalence) also follows a sig-
moidal function and can thus be conveniently repro-
duced. The model parameters age dependent early/
advanced adenoma progression are described by Gauss-
ian functions, since these functions provide maximal
flexibility allowing for a monotonously increasing or de-
creasing curve or a curve with a maximum.
Other model parameters are assumed to be stochas-
tic and hence are defined by an assumed probability
distribution. In this case the value for the individual
or the adenoma is drawn randomly from the respect-
ive distribution in each simulation run. The param-
eter will then remain constant throughout the lifetime
of the individual or adenoma. Examples include the
risk for new adenomas specific for an individual or a
progression risk specific for a given adenoma (see
below). Other parameters, e.g., the relative risk of
males versus females, are scaling factors for the re-
spective condition.
Please note that our parameters cannot be directly com-
pared to parameters from existing microsimulation
models since different strategies for the description of the
natural history of CRC were used [31]: For MISCAN, the
duration of an adenoma in a given state (not adenoma
progression rates) are used to describe the natural history
of CRC and duration of adenomas are drawn from an ex-
ponential distribution. For CRC-Spin, adenoma growth
follows a Janoschek growth model and CRC growth an ex-
ponential model. Finally, in SimCRC describing adenoma
initiation and progression follow logistic regression
curves, resembling our description of the natural history
of CRC closest. It should be noted that due to the limited
understanding of the natural history of CRC, the best
mathematical descriptions of adenoma and CRC initiation
and progression cannot be determined.
Simulating the natural history of CRC
At birth, an individual adenoma risk is assigned to
each individual, which defines high or low CRC risk
for this individual. At each time increment we decide
about initiation of an adenoma, at random, consider-
ing both the individual adenoma risk and the age
dependent adenoma risk. Upon adenoma initiation, an
adenoma specific progression risk will be assigned to
each adenoma. A high risk defines a quickly progres-
sing aggressive adenoma, whereas a low risk defines a
benign adenoma.
At each time increment, each adenoma might undergo
one of the following changes: i) Adenoma progression:
the risk for progression is determined by the product of
an age-dependent adenoma progression risk, the
Fig. 2 Location of adenomas and cancer within the colon. The large intestine has been divided into 13 relevant segments. The CMOST model
assumes location dependence for the progression and detectability of adenomas and cancers. Colonoscopy reaches the cecum in 95% of cases.
Rectosigmoidoscopy is easier to perform but limited in scope and meant to reach the left flexure in the majority of cases
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progression risk of the given adenoma, the progression
risk of the adenoma stage, and correction factors for fe-
male gender or rectal location if applicable. ii) Fast pro-
gression of adenoma to cancer: the risk of this event
depends on the age-dependent advanced adenoma pro-
gression rate, the stage of the adenoma, gender, and lo-
cation. iii) Adenoma regression: with very low
probability, regression of an adenoma (or disappearance
of a stage-I adenoma) is possible [32–36]; the risk of this
event is defined by the adenoma stage.
Initiation of CRC can happen via three different pathways
(Fig. 1): i) Progression of a stage 6 adenoma: this pathway
accounts for approximately two thirds of all carcinoma in
our microsimulation. ii) Fast progression of a smaller aden-
oma (stage 1-4) as described above. iii) Direct cancer with-
out adenomatous precursors; such a pathway was
introduced to match data from randomized endoscopic
CRC prevention trials [12, 15, 37, 38] regarding prevention
of right-sided adenomas after rectosigmoidoscopy screen-
ing. This direct cancer pathway represents cancers with
precursors difficult or impossible to detect by colonoscopy.
These cancers occur preferentially within the right colon
and the direct cancer pathway reflects the reduced efficacy
of CRC prevention by colonoscopy regarding right-sided
CRC [39, 40].
At initiation of a cancer a sojourn time, i.e., the
time from the initiation of the cancer to it becoming
symptomatic, is assigned to the cancer. The sojourn
time is drawn from a normal distribution of values
with a mean of 3 years [8, 41] and a standard devi-
ation of 0.5 years. The stage at which symptoms will
appear is chosen to reflect the stage distribution of
symptomatic cancers. The time spent in each stage is
also predefined for each cancer to reflect the stage
distribution of cancers detected during colonoscopy
screening [42].
After sojourn time a carcinoma will become symp-
tomatic, triggering a diagnostic colonoscopy. Upon
detection of a cancer, survival time will be defined,
following published survival rates for the respective
CRC stage [43]. Death from CRC is restricted to
5 years after CRC diagnosis.
In our microsimulation death results from colon can-
cer, medical interventions, or from other age-dependent
causes of mortality according to the 2008 US Life Table
Data [44]. An individual patient who dies of CRC is
Table 2 Description of the different parameters used in CMOST model. The procedure for calculating the parameters is described in
the supplementary information
Model parameter Properties Functional form
(where
applicable)
Age-dependent adenoma initiation risk Defined by a sigmoidal function. a01 þ exp − a1y−a2ð Þð Þ
Age-dependent early adenoma progression risk Defined by a Gaussian function. b0 exp(−(b1y −
b2)
2)
Age-dependent advanced adenoma progression risk Defined by a Gaussian function. c0 exp(−(c1y −
c2)
2)
Individual adenoma risk Cumulative density function describing the relationship between
population proportions and individual risk for appearance of new
adenomas. Defined by automatically calibrated anchor points.
Early and advanced adenoma specific progression risk Cumulative density function describing the relationship between
early or advanced adenoma proportions and adenoma specific
progression risk. Defined by manually calibrated anchor points.
Correction factors male/female for i) adenoma initiation ii)
early adenoma progression iii) advanced adenoma
progression
Constant
Correction factor rectum/colon for i) early adenoma
progression ii) advanced adenoma progression
Constant
Adenoma stage-specific progression risk Constant. One value for each adenoma stage 1-6, enables fine
tuning of the distribution of adenoma stages 1-6
Adenoma stage-specific regression risk Constant. One value for each adenoma stage (1-6 highest for 1,
lowest for 6); not calibrated
Adenoma stage-specific cancer risk Constant. One value for each adenoma stage (1 to 5), calibrated
to match prevalence of cancer in adenomas
Location specific direct cancer risk Constant. One value for each colon segment 1-13 (calibrated to
match CRC incidence reduction in rectosigmoidoscopy CRC
prevention study)
Prakash et al. BMC Medical Informatics and Decision Making  (2017) 17:80 Page 6 of 16
followed in the simulation until he would have died from
other causes.
Simulation of CRC screening
CMOST supports simulation of CRC screening and de-
tection by colonoscopy. For each colonoscopy, the
amount of colon visualized is drawn from a specified
distribution, with 95% of all colonoscopies reaching the
cecum on average. For each adenoma, our microsimula-
tion will determine whether the respective lesion will be
detected during a given intervention [45]. The probabil-
ity of detection depends on adenoma stage and whether
the lesion resided within the visualized colon. CMOST
also accounts for slightly reduced adenoma detection at
the hepatic and splenic flexure. CMOST considers the
following complications of colonoscopy: i) major bleed-
ing (4 per 10,000), ii) minor bleeding (11 per 10,000), iii)
mucosal burn (3 per 10,000) and iv) perforation (7 per
10,000) [46]. The probabilities of these complications are
derived from published data and increase 2-fold after
polypectomy [47].
Rectosigmoidoscopy is implemented similar to colon-
oscopy but with the limitation that the colon is visual-
ized only from rectum to the left-flexure (on average 6
of the 13 segments of the colon). Due to poor bowel
preparation and additional technical limitations, the
probability to detect an adenoma is assumed to be lower
than for colonoscopy (12.5% lower probability of detec-
tion for advanced adenomas and 25% for early adenomas
compared to colonoscopy). The risk of complications
during rectosigmoidoscopy is much lower than for col-
onoscopy [48] and no lesions will be removed. Any le-
sion detected at this intervention will trigger a
colonoscopy.
CMOST also supports additional screening interven-
tions including fecal occult blood test (FOBT) or im-
mune -FOBT. The parameters of all screening
intervention as well as adherence to screening and
follow-up colonoscopy can be freely adjusted. CMOST
allows for the definition of a screening plan with a start-
ing date, a finishing date, an adherence rate and a
screening interval.
Cost calculations
Our model includes costs for screening colonoscopy, po-
tential polypectomy, and procedural complications. In
our cost calculations, treatment costs during 5 years
after cancer diagnosis are considered. Treatment is di-
vided into three phases: The initial care phase lasting
3 months includes cancer detection, surgery and radi-
ation as well as chemotherapy in selected situations de-
pending on the stage and location of the carcinoma. In
case of death from CRC, the phase of terminal care lasts
up to 12 months and includes additional palliative
surgery in 50% and palliative chemotherapy in all pa-
tients. The period of continued treatment with moni-
toring and consultation visits spans from the end of
the initial phase to the beginning of the last year or
the end of treatment. Screening and treatment costs
(Additional file 1: Table S1) are based on the Diagno-
sis Related Group (DRG) codes for the outpatient set-
ting and Current Procedural Terminology (CPT)
codes for the inpatient setting, using the correspond-
ing Medicare reimbursement schedule (http://
www.cms.gov). Average national US payments for the
year 2012 are used in the present calculations. Costs
and life years gained are computed via comparison to
those that accrue in the non-screening scenario. Both,
costs and LYG are discounted by a 3% annual dis-
count rate. A list of costs used for our study is pro-
vided in Additional file 2: Tables S7 and Additional
file 3: Table S8.
Automated parameter calibration
CMOST supports automated calibration of model pa-
rameters to meet epidemiological benchmarks regard-
ing the natural history of colorectal cancer. To
calibrate our model to the US American population,
we used published age- and sex-specific adenoma
prevalence rates as benchmarks [18, 49–51]. Carcin-
oma incidence and mortality, as well as separate
colon and rectum cancer incidence rates, are modeled
according to data from the Surveillance Epidemiology
and End Results (SEER) database for 2005–2009 [52].
The stage distributions of symptomatic and asymp-
tomatic cancers also follow published analyses [11,
53]. Altogether we used 105 benchmarking data
points covering various quantities predicted by the
model for parameter estimation. A full list of all
benchmarks is provided in Additional file 1: Table S1.
Our strategy for automated parameter calibration is
explained in detail in Section V of the Supplement.
Briefly: we divide the natural history of CRC into four
steps (I: early adenoma, II: advanced adenoma, III:
cancer, IV: direct cancer) and perform calibration of
the group of parameters relevant for each of these
steps sequentially. Our implementation of the natural
history of CRC has been designed in a way that for
each calibration step a lower step will influence the
readouts of all higher steps but not vice versa. For in-
stance, adjusting parameters in step 1 to increase the
incidence of early adenomas by 10% will also change
the incidence of advanced adenomas by 10%. Vice
versa, modifying parameters of step 2 to increase ad-
enoma progression to increase advanced adenoma in-
cidence by 10% will affect early adenoma prevalence
to a lesser degree: Faster early adenoma progression
will decrease early adenoma prevalence since some
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early adenomas will be advanced adenomas now.
However, the decrease will only be approximately 1%
since prevalence of early adenomas is 10 times higher
than for advanced adenomas. For these reasons, all
four steps can be considered independent calibration
steps and are performed sequentially and sequential
calibrations yields in satisfactory results.
However, practical tests showed that even better
fitting could be achieved by a final calibration step
which simultaneously readjust parameters for step 2
and 3 simultaneously. Furthermore, our program
provides the option to automatically perform param-
eter calibration of steps 1-3 sequentially, followed by
a fine-tuning of parameters in steps 2 and 3 as a
single procedure (for instance on a cluster com-
puter). Details of these procedures are explained in
the Manual.
For each calibration, we used a heuristic greedy algo-
rithm followed by Nelder-Mead optimization [54] to
minimize the squared error between the benchmark
values and the corresponding model predictions for par-
ameter estimation. Automated parameter calibration is
required only when the benchmarks of the natural his-
tory are changed or when different possibilities for the
adenoma dwell time within the same natural history are
to be explored.
Implementation of CMOST
Details of all features of CMOST can be found in the
accompanying manual. The software is available under
a GNU general public license and can be downloaded
at https://gitlab.com/cmostmodel/CMOST. CMOST
has been implemented in Matlab®. Time critical
calculations were implemented using the Coder mod-
ule of Matlab, resulting in a 20x improvement in
performance.
All functionality of CMOST is available via several in-
tuitive graphical user interfaces. All relevant parameters,
including values for all variables describing the natural
history, specifications for CRC screening, and a screen-
ing plan, can be saved and loaded as a settings file.
CMOST can be run on a desktop computer and we pro-
vide basic support in the form of scripts for running it
on LINUX compute clusters.
CMOST produces the following output files after
each calculation: i) a Matlab data file with the raw
computation results, which can be used for further
calculations in Matlab; ii) several PDF files containing
plots of all relevant variables that describe the preva-
lence and distribution of adenomas, advanced aden-
omas, and CRC, relative to the benchmarks used; iii)
an Excel file with a summary of the CMOST simula-
tion run.
The accurate determination of the optimal age for
reduction in incidence, mortality, or cost per life
year gained required calculations on population sizes
of up to 10 million. The calculations are repeated
for each condition, e.g., the year of recommended
screening colonoscopy. Each of these cases is, in
principle, a single processor job. However, in order
to effectively handle the memory available on each
processor, the calculation on the population of 10
million was subdivided into calculations with
100,000 individuals on a high-performance LINUX
computer cluster.
Results
A new microsimulation model for the natural history of
CRC
We developed CMOST, a microsimulation model to
simulate CRC progression and the effect of CRC screen-
ing (Fig. 1). In our model carcinoma develops via early
and advanced adenoma precursors. Altogether, 6 aden-
oma stages and 4 carcinoma stages are considered in the
model. Most of the transition towards pre-clinical cancer
occurs via the adenomatous pathway, advancing through
the 6 successive stages of adenoma progression. With
lower probability, pre-clinical cancer can also start from
any of the adenoma stages or even from seemingly nor-
mal colon mucosa.
Our model accounts for the gender- and age-
dependent risks of adenoma development [5, 18, 50,
55] as well as the presence of multiple adenomas.
Each adenoma will be assigned one of 13 locations
within the colon, reflecting the distribution of aden-
oma lesions within the colon [24]. In our model, rec-
tum adenomas progress faster compared to colon
adenomas to achieve the expected proportion of rec-
tum cancers of all CRC [56]. Each individual within
the simulated patient population is assigned an indi-
vidual adenoma risk. The distribution of these risks
within the whole population is calibrated to match
the frequency of multiple adenomas [49] and also
matches the frequency of synchronous colorectal can-
cers of 3.5% of all CRC [57].
Adenoma dwell time indicates the time between ap-
pearance of an adenoma and transition to colorectal
cancer. Since adenoma dwell time can only be estimated
empirically with a broad margin of error, we considered
three parameterizations of CMOST with dwell times of
8, 13, and 19 years, referred to as CMOST8, CMOST13,
and CMOST19, respectively.
Automated calibration of our model
To calibrate our model for the North American or a
similar Western population, published age- and sex-
specific adenoma prevalence rates were used [18, 50,
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55]. Carcinoma incidence and mortality, as well as separ-
ate colon and rectum cancer incidence rates, are mod-
eled according to the data from the Surveillance
Epidemiology and End Results (SEER) data base for 2005–
2009 [52]. Altogether, 105 benchmarks were selected
(Additional file 1: Table S1) and an automated calibration
strategy was employed (see Additional file 4). A compari-
son with the benchmarks is performed at every iteration
of the automated parameter calibration. The calibration is
terminated when the comparisons are satisfactory, such as
shown in Fig. 3. CMOST allows the flexibility of including
a new set of CRC natural history benchmarks from a new
population, and the four-steps of the automated param-
eter calibration can be repeated.
CMOST assumes a fraction of all cancers to appear
without adenomatous precursors (referred to as direct
cancer henceforward). Benchmarking for direct cancer
was performed in an indirect way using data from a ran-
domized rectosigmoidoscopy study with 170,432 individ-
uals between 55 and 64 years of age [58]. After a one-
time only rectosigmoidoscopy (visualizing the left-sided
colon), individuals with positive findings are followed
by a full colonoscopy, thus enabling CRC prevention
on the left and the right side of the colon. Overall
CRC incidence reduction was used as a benchmark to
parameterize the rate of direct cancers (further details
in Additional file 4).
Simulation of CRC screening
In our microsimulation, colonoscopy will either be per-
formed according to a pre-defined screening schedule,
for adenoma or cancer surveillance, or for the diagnosis
of symptomatic cancer. Our implementation of colonos-
copy accounts for varying probabilities of successful
visualization of the hepatic and splenic flexures and im-
perfect detection of early and advanced adenomas and
colorectal cancer [45, 59]. Complications of colonoscopy
including major bleeding, which requires hospitalization;
minor bleeding, which does not require hospitalization;
perforation, which requires surgical treatment; and mu-
cosal burn, are all accounted for [60]. We also simulated
surveillance colonoscopies after the detection of a lesion–
according to current guidelines [61]. Other screening
interventions, including rectosigmoidoscopy and fecal
occult blood tests with various test parameters, have
also been implemented. Our program can be used to
assess effects of every CRC screening method including
DNA stool tests, DNA blood tests or imaging based
tests provided that information about test sensitivity,
specificity, risks and the costs are available.
Comparison of CMOST to randomized CRC screening
trials
To validate CMOST, we compared the predictions of
our model to the independent results of a large random-
ized controlled trial of endoscopy for CRC prevention
[37] (Table 3) that were not used for model calibration.
In this study, the effect of one or two rectosigmoidosco-
pies in a combined study group of 77,445 individuals
aged 55-74 years was tested over an 11.9-year follow-up
period. While the study is similar to the one used for
benchmarking the direct cancers [12], the study group is
slightly larger, start and end times differ, and two endos-
copies are used in a significant fraction of patients. Re-
sults of CMOST13 simulations compare well with the
intention-to-treat analysis of the randomized study and
its confidence intervals: CMOST13 predicts a similar
overall incidence reduction (19.9% predicted vs. 21% ob-
served), left-sided CRC incidence reduction (24% pre-
dicted vs. 29% observed) and overall mortality reduction
(26% predicted vs. 26% observed) [37]. Similar results
were obtained using CMOST8 and CMOST19 (Table 3).
A B C
Fig. 3 Results of CMOST regarding adenoma and cancer epidemiology for the whole population (males and females). a: Early adenoma prevalence b:
Advanced adenoma prevalence c: Cancer incidence. Literature-derived benchmarks (see Additional file 4) used for our microsimulation are indicated by
black squares and a blue dashed line; results of CMOST13 calculations are shown as a black line and green-squares when within 20% of benchmarks, and
as red-squares otherwise
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We also simulated other smaller CRC prevention studies
(Additional file 5: Table S9), and the simulation results
were also in agreement with the observed data [15, 38].
We conclude that CMOST reflects the natural history of
CRC well and reliably predicts the outcome of random-
ized rectosigmoidoscopy screening trials.
Comparison of CMOST with existing CRC simulation
models
Predictions of CMOST were compared to those of other
microsimulation models describing the natural history of
CRC, namely MISCAN, CRC-SPIN, and SimCRC,
following two previously published comparative studies
[7, 62]. In a first comparison, a hypothetical perfect
screening intervention, removing all lesions within the
colon of each individual (early adenomas, advanced ad-
enomas, and cancers) at the age of 65 was modeled (re-
ferred to as maximum clinical incidence reduction in the
original publication [7]). All CRC detected after the age
of 65 would thus be newly developed lesions. CMOST8,
CMOST13, and CMOST19 differ slightly regarding fu-
ture CRC incidence (Fig. 4). Predictions of CMOST8
strongly resemble predictions of MISCAN while
CMOST13 and CMOST19 predict a lower CRC incidence
20 years after the hypothetical intervention (Fig. 4). Add-
itional detailed comparisons between all microsimulation
models are provided in Additional file 6 Tables S2, Add-
itional file 7: Table S3, Additional file 8: Table S4, Add-
itional file 9: Table S5 and Additional file 10: Table S6.
We also tested predictions of CMOST with regard to
the effects of colonoscopy on colon cancer incidence
and mortality (Table 4) and found that CMOST was
closest to the MISCAN model. Since for all versions of
CMOST, i.e., CMOST8, CMOST13, and CMOST19 the
direct cancer rate was calibrated to achieve an identical
incidence reduction as a randomized rectosigmoido-
scopy study, predictions of all CMOST versions were
very similar. Thereby, the fraction of direct cancer is
lowest for CMOST8, intermediate for CMOST13, and
highest for CMOST19. Effects of a longer dwell time
(19 years for CMOST19, 13 years for CMOST13, leading
to longer lasting effects of adenoma removal than for
CMOST8) will be offset by a higher fraction of direct
cancers which cannot be prevented by CRC screening.
Without this calibration step (with identical direct can-
cer rates) incidence reduction for CMOST19 would be
highest, intermediate for CMOST13, and lowest for
CMOST8 (data not shown).
On a different note, CMOST was calibrated to reflect
contemporary CRC incidence, whereas MISCAN, CRC-
SPIN, and SimCRC reflect the higher CRC incidence of
1977 (before the onset of CRC screening). This differ-
ence explains some of the discrepancies within Table 4
(compare “CRC cases prevented” or “colonoscopies per
life year gained” for CMOST and the established
models). We also simulated the effect of FOBT screening
regarding CRC incidence and mortality reduction. The
results obtained by CMOST are similar to those from
SimCRC and MISCAN according to published data [63]
(Additional file 9: Table S5, Additional file 10 Table S6).
Taken together, predictions by CMOST regarding the
natural history of CRC development and CRC screening
are comparable to published microsimulation tools. All
versions of CMOST resulted in similar predictions for
various read outs, and predictions of CMOST strongly
resemble those of MISCAN.
Defining the optimal time point for colonoscopy
screening
We tested the optimal application of colonoscopy in a
scenario allowing for a single screening colonoscopy
Table 3 Effects of rectosigmoidoscopy screening for CRC prevention combined with 11.9-year follow-up (intention to treat analysis
according to the randomized controlled study by Schoen et al. [37])
Schoen et al. [37] with 95% CI CMOST8 CMOST13 CMOST19
Incidence reduction All CRC 21% (28-15) 20% 20% 20%
Right-sided CRC 14% (3-24%). 15% 7% 5%
Left-sided CRC 29% (20-36). 21% 24% 26%
Mortality reduction 26% (13-37) 23% 26% 23%
Fig. 4 Maximum clinical incidence reduction: The incidence of cancer
following a hypothetical perfect intervention which removes all
adenomas and undiagnosed cancers at age 65 is used to compare the
predictions of microsimulation models. MISCAN, CRC-SPIN, and SimCRC
data are from reference [7]
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during the lifetime of a patient. We compared incidence
and mortality of CRC to a scenario without screening
(Fig. 5a, b). For all versions of CMOST, incidence reduc-
tion from colonoscopy increases with age at first colon-
oscopy up to an optimum at approximately 58 years.
Both the extent of the benefit conferred by colonoscopy
(incidence reductions in CMOST8, CMOST13,
CMOST19 are 36%, 36%, and 35%, respectively) and the
optimal time point for colonoscopy were comparable for
all simulation models tested (59, 58, and 56 years;
Fig. 5a). Similarly, the mortality reductions predicted by
CMOST8, CMOST13, and CMOST19 are 43%, 40%,
and 39%, respectively, all at the optimal ages of 61, 60,
and 50 years (Fig. 5b).
We also calculated life years gained (LYG) and cost-
efficiency of colonoscopy. Following current practice in
health economics, LYG and costs were compared to the
standard scenario without screening. Differences were
Table 4 Comparison of CMOST with other microsimulation tools. Screening colonoscopies were performed at 10-year intervals be-
tween ages 50 and 75 years. Results of the microsimulation tools MISCAN, CRC-SPIN, and SimCRC were taken from reference [7].
Numbers indicate percentage reduction or the number of additional colonoscopies or CRC cases as indicated per 1000 individuals.
For CMOST, the numbers of the baseline scenario assuming a dwell time of 13 years (CMOST13) are given; numbers in parenthesis
indicate results obtained by using CMOST8 and CMOST19
MISCAN CRC-SPIN SimCRC CMOST13 (CMOST8, CMOST19)
Incidence reduction 52% 91% 82% 53% (55, 48)
Mortality reduction 65% 92% 84% 61% (65, 55)
Life years gained 207 260 327 142 (155, 121)
Screening colonoscopies 2288 2580 2574 2373 (2304, 2289)
Surveillance colonoscopies 1715 1341 1609 1311 (1222, 1251)
Total colonoscopies 4002 3921 4184 3600 (3538, 3558)
CRC cases prevented 30 56 54 27 (28, 23)
CRC mortality cases prevented 19 25 30 12 (13, 10)
Colonoscopies per case prevented 135 70 77 132 (124, 155)
Colonoscopies per LYG 19 15 13 25 (22, 29)
Fig. 5 Results of the effect of a single screening colonoscopy is performed at a specific age: a: Incidence reduction b: Mortality reduction c:
Discounted life years gained d: Discounted costs per discounted life year gained
Prakash et al. BMC Medical Informatics and Decision Making  (2017) 17:80 Page 11 of 16
discounted by 3% per year (Fig. 5c). Since prevention of
a carcinoma in a young patient will save more life years
compared to an older individual, the optimum for LYG
is at a lower age than for incidence and mortality reduc-
tion. For CMOST8, CMOST13, and CMOST19, 17, 16
and 14 discounted years per 1000 persons, respectively,
were obtained. An optimum was reached at similar time
points, (age 50, 49, and 49 years, respectively). Without
discounting, the number of LYG would be considerably
higher (102, 94, and 85 years per 1000 individuals) at
somewhat later time points (53, 54 and 53 years,
respectively).
Cost efficiency was estimated by dividing discounted
costs in USD by discounted LYG. By common conven-
tions in health economics, any intervention with costs
less than 100,000 USD per LYG is considered cost-
effective. In our calculations, the optimal values of cost-
efficiency for a single screening colonoscopy were
$14,209, $17,211, and $21,698 USD/LYG, and thus cost-
effective for all three versions of CMOST. As for inci-
dence and mortality reduction, the optimum cost-
effectiveness is attained at a similar age in all versions of
CMOST tested, i.e., for CMOST8, CMOST13, and
CMOST19, at 61, 59, and 56 years, respectively (Fig. 5d).
Discussion
We have introduced CMOST, a new microsimulation
model for the natural history of CRC. CMOST reflects
all basic characteristics of the natural history of CRC,
shows comparable characteristics to published models of
CRC microsimulation, and can reproduce the results of
a large randomized endoscopic screening intervention.
Our tool offers several benefits to the user. First, our
model is publicly available under a GNU General Public
License. This will enable independent reproduction of
predictions and advancement of the model and its im-
plementation. Furthermore, publication of all details of
our microsimulation will enable scrutiny and a detailed
discussion regarding all relevant aspects of CRC simula-
tions. We hope that future extensions of CMOST will
help increasing the validity of simulation results and fur-
ther improve the in silico design of CRC screening strat-
egies. Additional advancements of our model and its
implementation include calibration against results of a
recently published endoscopic screening trial, which had
not been possible at the time of the development of pre-
vious models. The transparency of benchmarking and
automated calibration of CMOST parameters will facili-
tate further improvements to the model. Repeated con-
vergence to the same set of parameters for different
initial parameter guesses suggests a well-defined
optimum in parameter space of CMOST.
We believe that many aspects of the CMOST imple-
mentation will benefit future users of the tool. CMOST
can be run using a graphical user interface, which allows
adjustment of all relevant parameters. Time critical rou-
tines are accelerated using the coder option of Matlab,
with a 20x improvement in performance. A simulation
of 100,000 individuals implemented in Matlab R2015
and executed on a 2.5 GHz processor, uses 1 GB RAM
and typically finishes in less than 1 min. In addition,
CMOST supports usage of a high-performance compute
cluster for either the simulation of large populations or
detailed explorations. There is no agreement as to what
level of detail is necessary for a CRC microsimulation to
be both accurate and practical. We attempted to imple-
ment CMOST as a detailed microsimulation. For in-
stance, 13 different locations of a lesion within the colon
are supported and many details of CRC pathogenesis
and screening can be adjusted according to these
locations.
Since the true value (or probability distribution) of ad-
enoma dwell times is unknown, we calibrated versions
of CMOST with median dwell times of 8, 13, and
19 years (CMOST8, CMOST13, CMOST19). Predictions
of CMOST8, CMOST13, and CMOST19 were similar
and showed resemblance to MISCAN. Due to our cali-
bration process, the longer dwell time of CMOST19
(leading to longer lasting effects of adenoma removal)
would be offset by a higher rate of direct cancer which
cannot be prevented by endoscopic screening. As in pre-
vious studies, when MISCAN, CRC-SPIN, and SimCRC
were frequently tested in parallel to increase robustness
of predictions, different versions of CMOST can be run
for increased robustness of predictions. Our data con-
firm adenoma dwell time as a critical parameter for the
natural history of CRC; however, we demonstrate that
after calibration for relevant clinical endpoints, similar
results can be achieved with models using considerably
different dwell times.
Currently available epidemiological data do not allow
for distinguishing whether CMOST8, CMOST13, or
CMOST19 reflects the natural history of CRC best. We
were unable to calibrate models with less than 8 years of
adenoma dwell time suggest that this parameter is
bounded, at least for a given set of benchmarks. Predic-
tions of all CMOST versions regarding overall CRC inci-
dence and mortality reduction and protection from left-
sided CRC were well within the confidence interval of a
large endoscopic CRC prevention trial. In the future, re-
sults of colonoscopy CRC prevention trials will further
inform microsimulation models regarding the preven-
tion of right-sided CRC.
According to the standard health economic defini-
tions, an intervention is considered cost-effective if the
costs remain below 100,000 USD per life year gained
[64, 65]. Colonoscopy screening in that sense is a cost-
effective intervention. In agreement with the results of
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numerous previous microsimulations [66, 67], screening
costs of a single screening colonoscopy remains below
the accepted limit of 100,000 USD per life years gained.
Our results also largely agree with an earlier study based
on a Markov model, recommending a single colonos-
copy at age 60 years as a highly cost-effective screening
strategy [68]. Several previous computational studies re-
ported an even better cost-effectiveness than our study,
and some studies even predicted CRC screening to be
cost saving [66]. These discrepancies are largely due to
different cost assumptions. Past studies used Medicare
data from the years 1999-2003 [46, 69] with some stud-
ies even considering the cost of death due to reasons
other than cancer. In contrast, the cost assumptions in
the present study were based on the Medicare reim-
bursement schedule from 2012. Therefore, in previous
microsimulations screening tended to be cheaper or
treatment costs were higher compared to ours, making
our cost calculations conservative.
Our tool provides flexibility to easily implement and
evaluate basically all CRC screening options provided in-
formation regarding test sensitivity, specificity, risks and
costs are provided. Examples include DNA based serum
and stool tests or imaging based screening methods. Fur-
thermore, big efforts are currently underway to ensure
the quality of colonoscopy as the most frequently used
CRC screening tools: Modifications in the procedure
such as endoscope inversion in the cecum to improve
adenoma detection there, adjustments in bowel prepar-
ation to improve “cleanliness” of the colon, enforcing a
retraction time of colonoscopy of at least 6 min have
been shown to increase adenoma detection rates. How-
ever, these procedures have direct or indirect costs
linked to a longer time of the investigation, higher de-
mands for documentation or patient and physician edu-
cation. Our tool will enable to assess the benefits of each
modification and put it into perspective by comparison
with increased costs. An incremental cost-effectiveness
ratio of 100’000 USD per LYG will determine, whether
any modification should be recommended or advised
against.
Our microsimulation has also several inherent limita-
tions: i) Key parameters of the natural history of CRC
are unknown. This is especially relevant for the adenoma
dwell time, the time from the appearance of an adenoma
until its transition to preclinical CRC. However, we pro-
vide three versions of CMOST spanning a wide range of
reasonable assumptions for this parameter, enabling sen-
sitivity analyses. ii) The serrated adenoma pathway is not
explicitly considered by our model. While implementa-
tion of an additional adenoma path with preferential dis-
tribution of serrated adenoma lesions in the right colon
and lower detectability by colonoscopy is technically
feasible, most characteristics of serrated adenoma
epidemiology remain unknown, reducing model calibra-
tion to guess work. However, our model allows for car-
cinoma directly developing from normal mucosa with a
right-colonic preference implemented, at least partially
accounting for the serrated adenoma path. iii) Our
model does not account for benign non-adenomatous
polyps. iv) CMOST has been calibrated to contemporary
CRC incidence data. This contrasts previous models,
which were calibrated using data of the year 1977, before
the introduction of CRC screening. For these reasons,
CRC incidence for MISCAN, SimCRC, and CRC-SPIN
remains higher than for CMOST. Several studies indi-
cate that the decrease in CRC incidence observed within
the last decades is not only due to CRC screening but
might also be due to usage of non-steroidal antirheu-
matic drugs [70] or changes in smoking [71] and nutri-
tion [72]. These different effects cannot be disentangled.
Conclusions
In summary, we have introduced CMOST, a new CRC
microsimulation tool, freely available under a general
public license. Predictions of our model regarding the
natural history of CRC and CRC screening were similar
to predictions of published CRC microsimulation tools
and an endoscopic CRC screening study, confirming the
validity of our model. CMOST predicts CRC screening by
colonoscopy to be highly cost-efficient with an optimal
time point of a single colonoscopy for maximum cost-
efficiency of approximately 61 years. Our computations
confirm adenoma dwell time as a critical parameter for
CRC microsimulation models; however, similar results for
various effects of colonoscopy screening including inci-
dence reduction, cost-efficiency, and optimal time points
were obtained with a dwell time of 8, 13, and 19 years.
Our tool enables assessment of many practical questions
in current gastroenterology. For instance, cost-effectiveness
of new CRC screening approaches, or of incremental
changes of existing screening approaches such as improve-
ments in colonoscopy screening by improved bowel prepar-
ation or physician training can be assessed. Additionally,
cost-effectiveness of CRC screening at extremes of age, co-
morbidities or risks could be addressed. Basically, most
practical question regarding screening or treatment of CRC
which can be expressed in terms of risks and costs, our tool
should be able to answer, perhaps after modification of the
code. Thereby, the flexibility of our model enables adapta-
tion also to countries with different CRC epidemiology such
as in developing countries. Additional case studies will im-
prove the practical value of our program in the future.
The main limitations of our tool is the limitation in our
knowledge of CRC, making assumptions for adenoma
dwell time and the distribution of risks for adenoma pro-
gression and initiation necessary. Furthermore, several as-
pects of the natural history of CRC such as the serrated
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adenoma pathway are not reflected by our program to
limit complexity. Results of ongoing randomized CRC
screening trials using colonoscopy (expected within 5-10
years) will improve the validity of predictions of our tool.
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